Antibody-oligonucleotide conjugates (AOCs) represent a rapidly expanding class of chimeric molecules that merge the precise target recognition of monoclonal antibodies with the functional, structural, or amplifiable properties of nucleic acids.
Read MoreThe global pharmaceutical landscape is undergoing a massive paradigm shift.
Read MoreA protein medicine can bind its target precisely and still struggle as a practical treatment.
Read MoreThe pharmaceutical landscape is undergoing a profound transformation with the rise of Live Biotherapeutic Products (LBPs).
Read MoreIt presents factual insights into how various regions and application areas have contributed to the overall expansion of this market in recent years.
Read More